REDWOOD CITY, Calif.,
April 25, 2018 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company, today announced that it will release first
quarter financial results after market close on Wednesday, May 9th, 2018. AcelRx management will
host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 9th, 2018 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers or (412) 902-4204 for international callers.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised setting. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The company has two
product candidates including DSUVIA™ (sufentanil sublingual tablet,
30 mcg), known as DZUVEO outside the
United States, with a proposed indication for the treatment
of moderate-to-severe acute pain in medically supervised settings,
and ZALVISO® (sufentanil sublingual tablet system, SST system, 15
microgram) being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-to-announce-first-quarter-2018-results-and-provide-a-corporate-update-on-wednesday-may-9th-2018-300636575.html
SOURCE AcelRx Pharmaceuticals, Inc.